SCHEMBL6039255

SCHEMBL6039255

Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCC2CCCO2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.71
ALDH1A1 P00352 3/20 0.57
MAPK1 P28482 1/20 0.55
CFTR P13569 1/20 0.54
HSD17B10 Q99714 2/20 0.53
LMNA P02545 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RCE1 Q9Y256 1/20 0.49
POLB P06746 2/20 0.49
NPSR1 Q6W5P4 1/20 0.48
SLC12A2 P55011 1/20 0.48
SLC12A5 Q9H2X9 1/20 0.48
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
EDNRA P25101 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038771 0.92 KDM4E (0.69) KDM4EALDH1A1MAPK1HSD17B10LMNA
SCHEMBL6038704 0.90 KDM4E (0.73) KDM4EALDH1A1MAPK1HSD17B10LMNA
SCHEMBL6039113 0.90 KDM4E (0.58) KDM4EALDH1A1MAPK1CFTRHSD17B10
SCHEMBL6038684 0.90 KDM4E (0.72) KDM4EALDH1A1MAPK1CFTRHSD17B10
SCHEMBL6038709 0.89 KDM4E (0.56) KDM4EALDH1A1MAPK1CFTRHSD17B10
SCHEMBL6038447 0.87 KDM4E (0.58) KDM4EALDH1A1MAPK1HSD17B10LMNA
SCHEMBL6038690 0.86 EDNRA (0.59) KDM4EALDH1A1CFTRHSD17B10LMNA
SCHEMBL6038985 0.85 EDNRA (0.58) KDM4EALDH1A1CFTRHSD17B10LMNA
SCHEMBL6038659 0.84 KDM4E (0.56) KDM4EALDH1A1HSD17B10LMNAMEN1
SCHEMBL6038571 0.80 MEN1 (0.58) KDM4EALDH1A1CFTRHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KDM4E 3561/4885ALDH1A1 2902/4885MAPK1 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.